Digesting The Legal Landscape After Landmark US Eylea Biosimilar Nods
Regeneron Attempting To Win Injunction, Biocon Biosimilar Case Likely Expedited
Executive Summary
The US Food and Drug Administration has given the green light for biosimilar competition to the near $6bn eye-disease juggernaut Eylea, but a major legal overhang is currently throttling the potential for any near-term launches. Generics Bulletin explores the lay of the land, including the recent scheduling conference in the now-consolidated trial involving five aflibercept biosimilar sponsors.